1Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol, 2001, 82(3) :532-537.
2Bristow RE, Tomacruz RS, Amstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 2002, 20 (5):1248-1259.
3Schwartz PE, Zheng W. Neoadjuvant chemotherapy for advanced ovarian cancer: the role of cytology in pretreatment diagnosis. Gynecol Oncol, 2003, 90(3) :644-650.
4Van der Burg MEL, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med, 1995, 332 (10):629-634.
5Rose PG, Nerenstone S, Brady M, et al. A phase Ⅲ randomized study of interval secondary cytoreducton in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a GOG study. Proc Am Soc Clin Oncol, 2002, 21: 20la.
6Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage ⅢC ovarian carcinoma. Cancer,2001,92(10) :2585-2591.
7Vergote I, De Wever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol, 1998, 71 (3) :431-436.
8Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.Cancer, 2001, 91 (12) :2329-2334.
9Van Dam PA, DeCloedt J, Tjalma WA, et al. Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer:can the risk be reduced? Am J Obstet Gynecol, 1999, 181 (3) :536-541.
7Boente MP, Chi DS, Hoskins WJ. The roles of surgery in the management of ovarian cancer primary and interval cytoreductive surgery[J]. Sere in Oncol, 1998,25 : 328- 334.
8Pectasides D, Famakis D, Koumarianou A, et al. The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer [J]. Oncology,2005,68( 1 ) :64 -70.
9Lee SJ, Kim BG, Lee JW, et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery[J]. Obstet Gynecol Res,2006,32( 1 ) :90- 106.
10Berek JS,Trope C, Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer[ J ]. Ann Oncol , 1999,10 ( suppl 1 ) : 3 -7.
